ClinicalTrials.gg
Not yet recruitingNCT06621667Updated Oct 1, 2024

Diaphragmatic Myofascial Release for Hyperkyphotic Subjects

An interventional study of diaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis and traditional physical therapy exercises for hyperkyphosis in Hyperkyphosis, sponsored by Cairo University. Not yet recruiting. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Study summary

kyphotic subjects have respiratory disturbances due to weakening of the diaphragm, responsible for inhalation, which lead to abnormalities in respiratory mechanics and abnormal gas exchange, leading to respiratory complications. Myofascial release of the diaphragm is an intervention intended to indirectly stretch the diaphragm muscle fibers to reduce muscle tension, normalize fiber length, and promote the efficiency of muscle contraction. Although diaphragm myofascial release has been used in clinical practice, to the best of the authors' knowledge, the current study is the first research investigating the effect of diaphragmatic myofascial release on lung function, chest mobility and kyphotic curve in hyperkyphotic subjects.

02

Conditions studied

  • Hyperkyphosis

Browse trials for

03

In context

Kyphosis

132 studies on the registry are indexed under Kyphosis; 31 are open to participants now.

This study's planned enrollment of 42 is close to the median of 44 across 82 interventional studies indexed under Kyphosis.

Browse Kyphosis studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant's age ranged from 20 to 40 years.
  • kyphosis angle 40-50◦
  • reporting pain on palpation of the diaphragm

Exclusion criteria

Exclusion Criteria:

  • A history of respiratory diseases, heart disease, vascular disease, central nervous system disorder, psychiatric disorders, hypertension.
  • History of any trauma or fracture to the thoracic spine.
  • inflammatory diseases such as rheumatoid arthritis, musculoskeletal problem and neurological deficit
  • Restrictive respiratory disease, smokers.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    study group

    Other: diaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis

  • Active comparator
    control group

    Other: traditional physical therapy exercises for hyperkyphosis

Interventions

  • Otherdiaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis

    diaphragmatic myofascial release

  • Othertraditional physical therapy exercises for hyperkyphosis

    traditional physical therapy exercises for hyperkyphosis

06

What researchers measure

Primary outcomes

  1. maximum voluntary ventilation

    the maximum voluntary ventilation will be measured using spirometer

    Time frame: change from base line at 4 weeks.

Secondary outcomes

  1. Chest expansion

    the chest expansion will be measured using tap measurement

    Time frame: change from base line at 4 weeks.

  2. kyphotic angle

    the kyphotic angle will be measured with flexicurve

    Time frame: change from base line at 4 weeks.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Dec 2024, 2 months later.

Of 56 non-industry interventional studies with no phase under Kyphosis, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's planned 2 months is below that.

Counting every sponsor, half of 58 studies reached it within 9 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2024
First posted
Oct 1, 2024
StartEst.
Oct 10, 2024
Primary completionEst.
Dec 20, 2024
CompletionEst.
Dec 30, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06621667
Lead sponsor
Cairo University
Responsible party
Marwa Shafiek Mustafa Saleh (assistance professor doctor, Cairo University) — Principal investigator
First posted
Oct 1, 2024
Start date
Oct 10, 2024 (estimated)
Primary completion
Dec 20, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Oct 1, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion